Blandine Pouleau

Title: Blandine Pouleau: Innovator in Bispecific Antibodies

Introduction

Blandine Pouleau is a prominent inventor based in La Chaux-de-Fonds, Switzerland. She has made significant contributions to the field of immunology, particularly in the development of bispecific antibodies. Her innovative work aims to address critical health challenges, including autoimmune and proliferative diseases.

Latest Patents

Blandine Pouleau holds a patent for her invention titled "CD47-CD38 bispecific antibodies." This novel class of bispecific heterodimeric immunoglobulins targets both the human CD47 antigen and the human CD38 antigen. The patent describes antibodies that comprise an anti-CD38 heavy chain variable region and a light chain variable region, as well as an anti-CD47 heavy chain variable region and a light chain variable region. The invention is particularly relevant for treating cancers, including hematologic malignancies and solid tumors.

Career Highlights

Blandine Pouleau is associated with Igi Therapeutics SA, where she continues to advance her research in immunotherapy. Her work is pivotal in developing new therapeutic strategies that can improve patient outcomes in cancer treatment.

Collaborations

Blandine collaborates with esteemed colleagues, including Laure Bouchez and Marie-Agnes Doucey. Their combined expertise enhances the research and development efforts at Igi Therapeutics SA.

Conclusion

Blandine Pouleau is a trailblazer in the field of bispecific antibodies, with a focus on innovative treatments for serious diseases. Her contributions are shaping the future of immunotherapy and hold promise for improving the lives of many patients.